Dr. Reem Karmali
Claim this profileNorthwestern University
Area of expertise
B-Cell Lymphoma
Reem Karmali has run 10 trials for B-Cell Lymphoma. Some of their research focus areas include:
Lymphoma
Reem Karmali has run 9 trials for Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Northwestern University
Northwestern Memorial Hospital
Clinical Trials Reem Karmali is currently running
Pembrolizumab + Tazemetostat
for Non-Hodgkin's Lymphoma
This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and tazemetostat may work better to treat patients who have received ASCT or CAR-T cell therapy for aggressive non hodgkins lymphoma.
Recruiting
1 award
Phase 2
Epcoritamab + Lenalidomide
for B-Cell Lymphoma
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immunotherapy that engages T-cells in the immune system to help redirect their killing effects against lymphoma cells. Lenalidomide can modulate the immune system to enhance killing effects of lymphoma by the immune system as well. Giving patients a combination of epcoritamab and lenalidomide may work better in treating refractory or relapsed immunodeficiency-related large B-cell lymphoma.
Recruiting
1 award
Phase 2
6 criteria
More about Reem Karmali
Clinical Trial Related
1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Reem Karmali has experience with
- Rituximab
- Cyclophosphamide
- Nivolumab
- Lenalidomide
- Pembrolizumab
- Prednisone
Breakdown of trials Reem Karmali has run
B-Cell Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Reem Karmali specialize in?
Reem Karmali focuses on B-Cell Lymphoma and Lymphoma. In particular, much of their work with B-Cell Lymphoma has involved MYC positive patients, or patients who are BCL2 positive.
Is Reem Karmali currently recruiting for clinical trials?
Yes, Reem Karmali is currently recruiting for 4 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Reem Karmali has studied deeply?
Yes, Reem Karmali has studied treatments such as Rituximab, Cyclophosphamide, Nivolumab.
What is the best way to schedule an appointment with Reem Karmali?
Apply for one of the trials that Reem Karmali is conducting.
What is the office address of Reem Karmali?
The office of Reem Karmali is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.